<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154662">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086501</url>
  </required_header>
  <id_info>
    <org_study_id>OXC-044/K</org_study_id>
    <nct_id>NCT01086501</nct_id>
  </id_info>
  <brief_title>ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients</brief_title>
  <official_title>Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Desitin Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Desitin Arzneimittel GmbH</source>
  <brief_summary>
    <textblock>
      The aim of the observational study is to investigate the safety of oxcarbazepine extended
      release (ER) during long-term therapy in epileptic patients. In addition, quality of life
      parameters should be documented if assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tolerability and safety</measure>
    <time_frame>12 months per patient</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">225</enrollment>
  <condition>Epilepsy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        newly diagnosed epileptic patients or patients who will be switched from other
        antiepileptic drugs to oxcarbazepine ER
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with focal epileptic seizures with or without secondary generalised
             tonic-clonic seizures

          -  mono- or combination therapy

          -  male and female from the age of 6

        Exclusion Criteria:

          -  hypersensitivity to oxcarbazepine MR or one of its excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Stephan Arnold</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand. 2004 Jun;109(6):374-7.</citation>
    <PMID>15147458</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>February 28, 2013</lastchanged_date>
  <firstreceived_date>March 12, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open, non-interventional</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
